Walgreens, Express Scripts, Rite Aid Corporation, CVS Caremark and St. Jude
Medical Inc. highlighted in Zacks Analyst Blog:
CHICAGO, Jan. 15, 2013
CHICAGO, Jan. 15, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Walgreens (WAG), Express Scripts
(ESRX), Rite Aid Corporation (RAD), CVS Caremark (CVS), and St. Jude Medical
Today, Zacks is promoting Four daily picks are offered free.
Here are highlights from Tuesday's Analyst Blog:
Walgreens Discusses Growth Strategy
Recently, Walgreens (WAG) debriefed the investors on its growth strategy for
fiscal 2013, while discussing the current business environment and providing a
recap of its performance in fiscal 2012.
Fiscal 2012 Recap
Despite a challenging year, Walgreens attained several milestones in fiscal
2012. The company made tuck-in acquisitions and forged a strategic partnership
with Alliance Boots. Further, Walgreens launched its Balance Rewards loyalty
program in September 2012, which has recorded more than 50 million
registrations to date.
The company generated record cash flow from operations of $4.4 billion in
fiscal 2012 out of which $1.9 billion was returned back to its shareholders
via stock repurchases and dividends. The payment of the largest quarterly
dividend in the company's history was another takeaway in the fiscal.
By adopting appropriate strategies, Walgreens was also able to convert its
fiscal 2012 headwinds into tailwinds for the ongoing fiscal. Among these, the
most important turnaround is the new multi-year pharmacy network agreement
with pharmacy benefit manager Express Scripts (ESRX) (from September 2012),
under which the company's pharmacy network has started filling prescriptions
from Express Scripts customers.
Growth Drivers for 2013 and Beyond
The company's three-pronged strategy of providing a holistic Well Experience,
improving the role of community pharmacy, and forging strategic alliances is
likely to yield positive results. Notably, the company has left no stone
unturned to bolster sales, ranging from a customer loyalty program to
stimulate consumer demand to resorting to inorganic means.
In order to supplement its Well Experience approach, Walgreens continues to
enhance its products and services. Moreover, the company is currently
investing in private brands such as Walgreens, Delish and Nice! among others.
Furthermore, Walgreens is the largest provider of vaccinations and
immunizations in the U.S., with respect to community pharmacy. As per
management, about 70% Americans are without a primary care physician and over
30 million of the U.S. population will gain insurance coverage in 2014 under
the health care reforms. Consequently, revenue contribution from this
franchise is expected to be more significant.
The strategic alliance with Alliance Boots has also allowed Walgreens to
expand its worldwide foothold, especially in Europe. The company believes that
the wholesale business of Alliance Boots should improve its supply-chain
performance. Also worth mentioning in this context is Walgreens' increasing
focus on emerging markets as the pharmaceutical sector in these markets
present significant growth opportunities.
The recent developments regarding Walgreens continues to display its strength
in pursuing strategic initiatives as reflected in the bullish momentum of its
stock price. The stock inched towards its 52-week high of $39.21 on January
Following its annual shareholders' meeting, estimate revision trends also
reflect a bullish sentiment toward Walgreens over the last 7 days. The
positive revisions in the Zacks Consensus Estimate for fiscal 2013 as well as
fiscal 2014 underline these events.
While fiscal 2012 was a challenging year for Walgreens, we look forward to
fiscal 2013 with sublime optimism. We currently have a long-term Neutral
recommendation on the stock which carries a Zacks Rank #3 (Hold). Its peers
Rite Aid Corporation (RAD) carries a Zacks Rank #1 (Strong Buy) and CVS
Caremark (CVS) carries a Zacks Rank #2 (Buy).
St. Jude Reports Prelim 4Q Results
Medical devices major, St. Jude Medical Inc. (STJ) released preliminary
results for the 2012-fourth quarter. The company will report its financial
results on Jan 23, before markets opens.
St. Jude expects adjusted earnings for the quarter in the range of 90 cents—92
cents per share, surpassing its earlier guidance of 86 cents–88 cents. This
compared with the Zacks Consensus Estimate of 89 cents for the quarter.
Adjusted earnings exclude one-time item charges of 50 cents–60 cents per share
related to restructuring and other corporate activities. Management stated
that sales growth and cost reduction measures will lead to the improvement in
Total revenues for the quarter, on a constant currency basis, are projected to
be $1,372 million, down 1% year over year. The Zacks Consensus Estimate for
revenues is $1,370 million.
Based on the above projections, revenues from the core Cardiac Rhythm
Management (CRM) business declined 6% (5% on a constant currency basis) to
$682 million. Within CRM, Implantable cardiac defibrillators (ICD) revenues
were down 3% at $422 million. This segment continues to be plagued by the
Durata lead issues. Pacemaker revenues declined 11% to roughly $260 million.
Neuromodulation revenues decreased 7%, (down 6% in constant currency) year
over year to $113 million. Revenues from St. Jude's Cardiovascular segment
inched down 1% (up 1% in constant currency) to $338 million. Within
Cardiovascular segment, structural heart devices revenues increased 1% to $152
million but the same from vascular offerings dipped 2% to $186 million.
However, on a positive note, Atrial Fibrillation (AF) revenues climbed 10% (up
11% in constant currency) to $239 million in the quarter.
About the company
St. Jude, with a market cap of $11.80 billion, is a leading medical devices
manufacturer maintaining a solid rate of growth over the past decade. We are
impressed by the company's efforts in leveraging its margins by undertaking
various restructuring initiatives and controlling expenses.
Today, Zacks is promoting Four daily picks are offered free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.